

**IC06 Rec'd PCT/PTO 24 AUG 2005**

IN THE UNITED STATES RECEIVING OFFICE (RO/US) '  
Designated/Elected Office (DO/EO/US)

U.S. Application No.: 10/530,606 ✓  
U.S. National Stage of  
International Application No.: PCT/EP2003/011240  
International Filing Date: 10 October 2003  
Earliest Priority Date: 10 October 2002  
Applicants: Hans Boman, Mats Andersson, Katrin Pütsep and  
Göran Carlsson  
Title: METHOD FOR DETERMINING THE SUSCEPTIBILITY OF A  
SUBJECT TO INFECTION  
Attorney's Docket No.: 3612.1001-000

Date: 8-24-05

EXPRESS MAIL LABEL NO. EV 214 880 945 US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:  
☐ a Statement under 37 CFR 1.97(e), as checked below, or  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:  
☐ a Statement under 37 CFR 1.97(e), as checked below, and  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application  
filewrapper.  
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
  - ☒ Copies of the cited references are enclosed.
    - ☒ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
  - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [       ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
  - ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
  - ☐ The "concise explanation" requirement (non-English references) for references [       ] under 37 CFR 1.98(a)(3) is satisfied by:
    - ☐ the explanation provided on the attached sheet.
    - ☐ the explanation provided in the Specification.
    - ☐ submission of the enclosed International Search Report.
    - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
    - ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.


Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.


By



Alice O. Carroll  
Registration No.: 33,542  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:



PTO-1449 REPRODUCED  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>August 23, 2005</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3612.1001-000		APPLICATION NO. 10/530,606	
	FIRST NAMED INVENTOR Hans Boman		PCT FILING DATE 10 October 2003	
	EXAMINER	CONFIRMATION NO.	GROUP	

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AD	US 2002/0072495 A1	06-13-2002	Chertov <i>et al.</i>
	AF			
	AF			
	AG			
	AH			
	AH			
	AH			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>August 23, 2005</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3612.1001-000		APPLICATION NO. 10/530,606	
	FIRST NAMED INVENTOR Hans Boman		PCT FILING DATE 10 October 2003	
	EXAMINER	CONFIRMATION NO.	GROUP	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AR2	Agerberth, <i>et al.</i> , "The Human Antimicrobial and Chemotactic Peptides LL-37 and $\alpha$ -Defensins are Expressed by Specific Lymphocyte and Monocyte Populations," <i>Blood</i> , 96(9):3086-3093 (November 1, 2000).
AS2	Bals, <i>et al.</i> , "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide," <i>Infection and Immunity</i> , (67)11:6084-6089 (November 1999).
AT2	Bals, R., "Epithelial Antimicrobial Peptides in Host Defense Against Infection," <i>Respiratory Research</i> , 1(3):141-150 (2000).
AU2	Baranova, <i>et al.</i> , "Alkaline Phosphatase Activity in Neutrophils From Patients With Severe Congenital Neutropenia (Kostmann's Syndrome)," <i>International Journal of Hematology</i> , 70:236-240 (1999).
AV2	Boman, H., "Peptide Antibiotics and Their Role in Innate Immunity," <i>Annual Review of Immunology</i> , 13:61-92 (1995).
AW2	Borregaard N. and Cowland J.B., "Granules of the Human Neutrophilic Polymorphonuclear Leukocyte," <i>Blood</i> , 89(10):3503-3521 (May 15, 1997).
AX2	Bülöw, <i>et al.</i> , "Sorting of Neutrophil-Specific Granule Protein Human Cathelicidin, hCAP-18, When Constitutively Expressed in Myeloid Cells," <i>Journal of Leukocyte Biology</i> , 72:147-153 (July 2002).
AY2	Carlsson, G. and Fasth, A., "Infantile Genetic Agranulocytosis, Morbus Kostmann: Presentation of Six Cases From the Original "Kostmann Family" and a Review," <i>Acta. Pediatr.</i> , 90:757-764 (2001).
AZ2	Dale, <i>et al.</i> , "Localized Antimicrobial Peptide Expression in Human Gingiva," <i>Journal of Periodontal Research</i> , 36:285-294 (2001).
AR3	Defraia, E. and Marinelli, A., "Oral Manifestations of Congenital Neutropenia or Kostmann Syndrome," <i>The Journal of Clinical Pediatric Dentistry</i> , 26(1): 99-102 (2001).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  August 23, 2005  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3612.1001-000		APPLICATION NO. 10/530,606	
	FIRST NAMED INVENTOR Hans Boman		PCT FILING DATE 10 October 2003	
	EXAMINER	CONFIRMATION NO.	GROUP	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AS3	Roester, <i>et al.</i> , "In Vitro Functions of Neutrophils Induced by Treatment With rhG-CSF in Severe Congenital Neutropenia," <i>Eur. J. Haematol.</i> , 46:112-118 (1991).
AT3	Ganz, <i>et al.</i> , "Microbicidal/Cytotoxic Proteins of Neutrophils Are Deficient in Two Disorders: Chediak-Higashi Syndrome and "Specific" Granule Deficiency," <i>J. Clin. Invest.</i> , 82:552-556 (August 1988).
AU3	Gudmundsson, <i>et al.</i> , "Structure of The Gene for Porcine Peptide Antibiotic PR-39, A Cathelin Gene Family Member: Comparative Mapping of The Locus for The Human Peptide Antibiotic FALL-39," <i>Proc. Natl. Acad. Sci., USA</i> , 92:7085-7089 (July 1995).
AV3	Gudmundsson, <i>et al.</i> , "The Human Gene FALL39 and Processing of The Cathelin Precursor to The Antibacterial Peptide LL-37 in Granulocytes," <i>Eur. J. Biochem.</i> , 238:325-332 (1996).
AW3	Guthmiller, <i>et al.</i> , "Susceptibilities of Oral Bacteria and Yeast to Mammalian Cathelicidins," <i>Antimicrobial Agents and Chemotherapy</i> , 45(11):3216-3219 (November 2001).
AX3	Huttner, K.M. and Bevins, C.L., "Antimicrobial Peptides as Mediators of Epithelial Host Defense," <i>Pediatric Research</i> , 45(6):785-794 (1999).
AY3	Nagaoka, <i>et al.</i> , "Synergistic Actions of Antibacterial Neutrophil Defensins and Cathelicidins," <i>Inflammation Research</i> , 49:73-79 (2000).
AZ3	Slots, J., "Actinobacillus Actinomycetemcomitans and Porphyromonas Gingivalis in Periodontal Disease: Introduction," <i>Periodontology</i> 2000, 20:7-13 (1999).
AR4	Sørensen, <i>et al.</i> , "An ELISA for hCAP-18, The Cathelicidin Present in Human Neutrophils and Plasma," <i>Journal of Immunological Methods</i> , 206:53-59 (1997).
AS4	Sørensen, <i>et al.</i> , "Human Cathelicidin, hCAP-18, is Processed to The Antimicrobial Peptide LL-37 by Extracellular Cleavage With Proteinase 3," <i>Blood</i> , 97(12):3951-3959 (June 15, 2001).
AT4	Tanaka, <i>et al.</i> , "Sensitivity of Actinobacillus Actinomycetemcomitans and Capnocytophaga spp. to The Bactericidal Action of LL-37: A Cathelicidin Found in Human Leukocytes and Epithelium," <i>Oral Microbiology and Immunology</i> , 15:226-231 (2000).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>August 23, 2005</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3612.1001-000		APPLICATION NO. 10/530,606	
	FIRST NAMED INVENTOR Hans Boman		PCT FILING DATE 10 October 2003	
	EXAMINER	CONFIRMATION NO.	GROUP	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AU4	Turner, <i>et al.</i> , "Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils," <i>Antimicrobial Agents and Chemotherapy</i> , 42(9):2206-2214 (September 1998).
AV4	Van Dyke, T.E. and Vaikuntam, J., "Neutrophil Function and Dysfunction in Periodontal Disease," <i>Current Opinion in Periodontology</i> , pp. 19-27 (1994).
AW4	van Winkelhoff, <i>et al.</i> , "Microbiology of Destructive Periodontal Disease in Adolescent Patients With Congenital Neutropenia," <i>Journal of Clinical Periodontology</i> , 27:793-798 (2000).
AX4	Zasloff, M., "Antimicrobial Peptides of Multicellular Organisms," <i>Nature</i> , 415:389-395 (January 24, 2002).

EXAMINER	DATE CONSIDERED
----------	-----------------